MDACC Study No:2013-0207 ( NCT No: NCT01891344)
Title:A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal Investigator:Robert Coleman
Treatment Agent:Rucaparib
Study Status:Open
Study Description:This clinical research study is made up of 2 parts. The goal of Part 1 was to
learn if biomarkers (substances in the body including DNA and RNA [the genetic
materials in cells]) may be related to your reaction to the study drug. The
goal of Part 2 is to learn if the experimental drug CO-338 (rucaparib) can
help to control epithelial ovarian, fallopian tube, and/or primary peritoneal
cancer. The safety of the drug will also be studied. This consent form is for
Part 2.
Hide details for General InformationGeneral Information

Disease Group:Gynecology
Phase of Study:Phase II
Treatment Agents:Rucaparib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Clovis Oncology
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Coleman
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-745-3357
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults